Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 480

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 480
---
ASB ASC Topic 718. The
assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 6 to our
Financial Statements for the year ended December 31, 2024 included in this Report

(4)
Amounts represent health insurance premiums paid.

(5) Amounts represent health insurance premiums paid,
car payments, car insurance payments, and club memberships costs.

Executive
Compensation Arrangements

Below
is a more detailed summary of the elements of our current executive compensation program as it relates to our named executive officers.

61

Employment
Agreements 

Erez
Aminov

 Effective
August 12, 2024, we entered into an employment agreement with Mr. Aminov, pursuant to which Mr. Aminov will serve as our Chief Executive
Officer and Chairman of our Board. Under his employment agreement, Mr. Aminov has agreed to devote reasonable business time and effort
to the business and affairs of the Company. Mr. Aminov’s employment agreement provides that his employment will be on an at-will
basis and can be terminated by either Mr. Aminov or our company at any time and for any reason. Under the agreement, Mr. Aminov will
receive a base salary of $0.275 million per year. In the event that Mr. Aminov’s employment is terminated by our company without
“Cause” or is terminated by Mr. Aminov for “Good Reason”, Mr. Aminov will be entitled to (1) be paid an amount
equal to Mr. Aminov’s annual base salary, which payment shall be made seventy-five percent (75%) in a lump sum within thirty (30)
days following the effective date of the general release of claims (following any revocation period) and twenty-five percent (25%) as
salary continuation payments in substantially equal installments over the six (6) months following the release effective date in accordance
with our customary payroll practices commencing on the first payroll date following the release effective date, and (2) receive twelve
(12) months’ accelerated vesting of any stock options that are outstanding and unvested as of such termination, such that any outstanding
and unvested stock options that would have vested during the twelve- (12) month period following the termination date had Mr. Aminov
remained employed in good standing shall become immediately vested and